Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
NCT04238091 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2022-03-21
Summary
The purpose of this study is to examine fecal transfer as a potential treatment for Alopecia Areata (AA). This trial will attempt to discover if fecal transfer can treat immune-related hair loss.
Conditions
- Alopecia Areata
- Alopecia Totalis
- Alopecia Universalis
Interventions
- DRUG
-
Fecal material transfer therapy
Fecal microbiota transplants will be performed as follows: FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels. Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position. One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not.
- PROCEDURE
-
4mm Punch Biopsy of Scalp
For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
- DIAGNOSTIC_TEST
-
Blood draw
Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
- PROCEDURE
-
Skin Microbiome sampling
Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
- PROCEDURE
-
Hair Microbiome Sampling
Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
- DRUG
-
Pre-FMT Antibiotic Cocktail
For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
- DRUG
-
Bowel Prep
The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
Sponsors & Collaborators
-
Lindsey Bordone
lead OTHER
Principal Investigators
-
Lindsey Bordone, MD · Columbia University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-19
- Primary Completion
- 2022-03-02
- Completion
- 2022-03-02
- FDA Drug
- Yes
More Related Trials
-
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
NCT00408798 ·Status: COMPLETED ·Phase: NA
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT06826196 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
NCT02018042 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia
NCT06482541 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
NCT07107841 ·Status: RECRUITING ·Phase: NA
-
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
NCT04011748 ·Status: UNKNOWN ·Phase: PHASE2
-
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
NCT04239521 ·Status: COMPLETED
-
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
NCT04882969 ·Status: WITHDRAWN ·Phase: NA
-
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
NCT04207931 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
NCT03941548 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
NCT06854432 ·Status: TERMINATED ·Phase: NA
-
The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia
NCT03048461 ·Status: WITHDRAWN ·Phase: PHASE2
-
LEO 124249 Ointment in the Treatment of Alopecia Areata
NCT02561585 ·Status: COMPLETED ·Phase: PHASE2
-
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
NCT04341363 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
NCT06484881 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
NCT05332366 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial to Evaluate Effectiveness of a Probiotic Preparation Administered to Patients With Alopecia Areata
NCT05599607 ·Status: COMPLETED ·Phase: NA
-
A Study of Secukinumab for the Treatment of Alopecia Areata
NCT02599129 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
NCT04784533 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
NCT03811912 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
NCT03532958 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
NCT02299297 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
NCT01950780 ·Status: COMPLETED ·Phase: PHASE2